Nexcella, Inc. a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced tha...
GC Cell Corporation (hereinafter referred to as "GC Cell"; 144510:KOSDAQ) and Lukas Biomedical Co., Ltd. (hereinafter referred to as "Lukas," TWSE ...
The Biosecure Act is a significant legislative proposal aimed at reshaping the pharmaceutical supply chain landscape, particularly concerning the s...
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to ...
net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entr...
CordenPharma is making a record investment of ~€900m over the next 3 years in expanding its peptide platform, both at its Colorado, US site and in...
Certara, Inc. a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leadi...
Certara, Inc. a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leadi...
Biotechnology company Apriori Bio has been awarded US $1.1 million from CEPI to advance its biology-informed artificial intelligence platform Octavi...
Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) announced a definitive agreement for Lilly to acquire Mor...
Roche announced that the United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6.0 mg single-dose pre...
Biogen Inc. has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company foc...
Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for PYZCHIVA&re...
Nxera Pharma announces that it has reached an important R&D milestone under its multi-target discovery collaboration with AbbVie targeting neur...
© 2024 Biopharma Boardroom. All Rights Reserved.
